On September 11th, after the market closed, the management team at Aurora Cannabis (ACB) announced financial results for the fourth quarter of the company’s 2019 fiscal year. Heading into earnings, there was a lot of tension built up, not necessarily because of Aurora specifically, but because the industry, in recent months, has been in the doldrums. While 2019 started out as a year where investors focused on growth at all costs in the space, this attitude has quickly shifted and now any performance that doesn’t match both growth expectations and profitability expectations is